CoChat
Sign Up
Cited by 660Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesNicotinic Acetylcholine Receptors Study

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Effect of Maintenance Therapy With Varenicline on Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Tonstad, Serena·2006·JAMA
DOI 10.1001/jama.296.1.64
Open this paper in CoChat — free account

Abstract

CONTEXT: The majority of cigarette smokers who achieve abstinence relapse within the first year and require many attempts before achieving permanent abstinence. Evidence to support pharmacological treatment for relapse prevention is insufficient. OBJECTIVE: To determine whether smokers who quit after 12 weeks of treatment with varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, maintain greater continuous abstinence rates (defined as not a single "puff" of a cigarette) than placebo controls during an additional 12 weeks of treatment and until 52 weeks after treatment initiation. DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial conducted at multiple medical clinics in 7 countries with follow-up to 52 weeks after study baseline. Of 1927 cigarette smokers recruited between April 2003 and February 2004 and treated for 12 weeks with open-label varenicline titrated to 1 mg twice per day, 1236 (64.1%) did not smoke, use tobacco, or use nicotine replacement therapy during the last week of treatment and 62.8% (n = 1210) were randomized to additional treatment or placebo. INTERVENTION: Participants were randomly assigned to receive either double-blind varenicline, 1 mg twice per day (n = 603), or placebo (n = 607) for an additional 12 weeks. MAIN OUTCOME MEASURES: Carbon monoxide-confirmed continued abstinence during weeks 13 to 24 and weeks 13 to 52 of the study. RESULTS: The carbon monoxide-confirmed continuous abstinence rate was significantly higher for the varenicline group than for the placebo group for weeks 13 to 24 (70.5% vs 49.6%; odds ratio [OR], 2.48; 95% confidence interval [CI], 1.95-3.16; P<.001) as well as for weeks 13 to 52 (43.6% vs 36.9%; OR, 1.34; 95% CI, 1.06-1.69; P = .02). Adverse events reported in the open-label period were mostly mild; no difference in adverse events between varenicline and placebo was observed during the double-blind period. CONCLUSIONS: Smokers who achieved abstinence for at least 7 days at the end of 12 weeks of open-label varenicline treatment and were randomized to receive an additional 12 weeks of varenicline treatment showed significantly greater continuous abstinence in weeks 13 to 24 compared with placebo. This advantage was maintained through the nontreatment follow-up to week 52. Varenicline may be an efficacious, safe, and well-tolerated agent for maintaining abstinence from smoking. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00143286.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.296.1.64

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

Sorted by citations

Items 101–200 of 660

Related

See all

Metadata

Authors
Tonstad, S.
Affiliations
University of Oslo (NO)
Corresponding author
Tonstad, Serena
ORCID
Tonstad, Serena
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2006-07-05
Volume
296
Issue
1
Pages
64
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.296.1.64
OpenAlex
W2053457282
Cited by
660
References
23
Citations by year
2026: 5 · 2025: 6 · 2024: 12 · 2023: 12 · 2022: 11 · 2021: 13 · 2020: 31 · 2019: 14 · 2018: 20 · 2017: 15 · 2016: 23 · 2015: 34 · 2014: 24 · 2013: 35 · 2012: 47
FWCI
54.35
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cardinal Health
  • Universitetet i Oslo
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
varenicline, smoking cessation, relapse prevention, maintenance therapy, continuous abstinence, nicotine dependence, α4β2 nicotinic acetylcholine receptor, long-term follow-up, adverse events, nicotine replacement therapy, smoking cessation clinics, smoking cessation services
MeSH terms
Varenicline, Adult, Benzazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review